Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

Jefferson Medical College of Thomas Jefferson University

2011, Philadelphia, PA

Residency

Pediatrics

Children's National Medical Center

2014, Washington, DC

Fellowship

Pediatric Hematology/Oncology

Children's Hospital Los Angele

2017, Los Angeles, CA

Fellowship

Pediatric Neuro-Oncology

Children's Hospital Los Angeles

2018, Los Angeles, CA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Yeo earned his medical degree at Jefferson Medical College of Thomas Jefferson University in 2011. After internship and residency training at Children's National Medical Center, he completed a pediatric Hematology/Oncology and a pediatric neuro-oncology fellowship at Children's Hospital Los Angeles. He was subsequently recruited to join the Dana-Farber/Boston Children's Cancer and Blood Disorders Center as an attending physician and clinician-researcher.

His interests are in the development and conduct of early phase clinical trials, the care of adolescent and young adult (AYA) with primary CNS tumors, and medical education. Dr. Yeo currently leads the AYA neuro-oncology program and the pediatric neuro-oncology fellowship program.

Publications

  1. Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Cell Rep Med. 2025 May 20; 6(5):102095. View Abstract

  2. Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience. Pediatr Blood Cancer. 2025 May; 72(5):e31628. View Abstract

  3. The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation. J Neurooncol. 2025 May; 173(1):167-177. View Abstract

  4. Intracranial germ cell tumors: advancement in genomic diagnostics and the need for novel therapeutics. Front Oncol. 2025; 15:1513258. View Abstract

  5. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions. Neuro Oncol. 2025 Jan 12; 27(1):13-32. View Abstract

  6. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro Oncol. 2024 Dec 05; 26(12):2364-2376. View Abstract

  7. Clinical utility of DNA methylation profiling for choroid plexus tumors. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae097. View Abstract

  8. Pediatric-type low-grade gliomas in adolescents and young adults-challenges and emerging paradigms. Childs Nerv Syst. 2024 Oct; 40(10):3329-3339. View Abstract

  9. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024 Apr; 13(8):e7154. View Abstract

  10. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol. 2024 02 02; 26(2):348-361. View Abstract

  11. H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications. J Neuropathol Exp Neurol. 2023 12 22; 83(1):30-35. View Abstract

  12. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro Oncol. 2023 01 05; 25(1):199-210. View Abstract

  13. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdac182. View Abstract

  14. Primary central nervous system germ cell tumors in children and young adults: A review of controversies in diagnostic and treatment approach. Neoplasia. 2023 Feb; 36:100860. View Abstract

  15. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol. 2022 11 02; 24(11):1964-1975. View Abstract

  16. CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past. Neuro Oncol. 2022 11 02; 24(11):1962-1963. View Abstract

  17. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Abstract

  18. PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. Mod Pathol. 2022 12; 35(12):1770-1774. View Abstract

  19. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View Abstract

  20. Clinical Trial Enrollment Among Adolescent and Young Adults with Primary Central Nervous System Tumors Treated at the Dana-Farber Cancer Institute. J Adolesc Young Adult Oncol. 2022 12; 11(6):543-549. View Abstract

  21. The epidemiology of primary and metastatic brain tumors in infancy through childhood. J Neurooncol. 2022 Jan; 156(2):419-429. View Abstract

  22. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022 01 13; 139(2):256-280. View Abstract

  23. Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatr Blood Cancer. 2021 10; 68(10):e29172. View Abstract

  24. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Cancer Immunol Immunother. 2022 Jan; 71(1):153-164. View Abstract

  25. IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 07; 34(7):1236-1244. View Abstract

  26. Adolescent and young adult neuro-oncology: a comprehensive review. Neurooncol Pract. 2021 Jun; 8(3):236-246. View Abstract

  27. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Abstract

  28. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clin Pharmacokinet. 2021 03; 60(3):283-303. View Abstract

  29. Response to Letter by Walker et al. Neurooncol Pract. 2020 Oct; 7(5):574-575. View Abstract

  30. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View Abstract

  31. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020 Aug; 149(1):113-122. View Abstract

  32. Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. J Neurooncol. 2020 May; 147(3):721-730. View Abstract

  33. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. J Neurooncol. 2019 Nov; 145(2):375-383. View Abstract

  34. Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355. View Abstract

  35. Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. Pediatr Blood Cancer. 2019 12; 66(12):e27983. View Abstract

  36. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract. 2020 Jan; 7(1):4-10. View Abstract

  37. Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution. JCO Precis Oncol. 2019; 3. View Abstract

  38. HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates. J Immunol. 2019 03 01; 202(5):1465-1478. View Abstract

  39. A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. J Neurooncol. 2018 Dec; 140(3):575-582. View Abstract

  40. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol. 2018 May; 138(1):199-207. View Abstract

  41. The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report. J Pediatr Hematol Oncol. 2016 08; 38(6):489-90. View Abstract

  42. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 07; 38(5):345-9. View Abstract

  43. Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide. J Neurosurg Pediatr. 2013 Jun; 11(6):682-6. View Abstract

  44. Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatr Blood Cancer. 2012 Jun; 58(6):986-7. View Abstract

  45. Brain Tumors in Children. Germ Cell Tumors. pp.251-264.
BESbswy